Definium Therapeutics, Inc. (DFTX) Stock Price & How to Invest

Definium Therapeutics (Nasdaq: DFTX) is a clinical-stage biopharmaceutical company focused on brain-health and psychiatric disorders. It is the rebranded MindMed, having changed its name from Mind Medicine (MindMed) Inc. in January 2026. Its lead asset is DT120 ODT (formerly MM120), a proprietary orally disintegrating tablet formulation of lysergide (LSD) tartrate being developed for generalized anxiety disorder (GAD) and major depressive disorder (MDD), alongside DT402, an earlier-stage candidate in autism spectrum disorder (ASD). In June 2026 the company reported that its Phase 3 Emerge trial of DT120 in MDD met its primary and key secondary endpoints, and in September 2026 it reported that Panorama, a second Phase 3 trial in GAD, also met its primary endpoint. A pre-NDA meeting with the FDA is scheduled for the fourth quarter of 2026, with an NDA submission planned for the first half of 2027.

The investment picture is that of a high-risk, high-reward development-stage biotech rather than an operating business. Definium generates essentially no product revenue and posts recurring net losses funded by its balance sheet, which held roughly $373 million in cash and investments at March 31, 2026 before a follow-on equity raise of about $700 million to support regulatory and commercialization plans. By June 30, 2026 cash stood at about $1.08 billion against roughly $36 million of debt, and the net loss for the second quarter of 2026 widened to about $159 million (EPS of -$1.44 versus a -$0.55 estimate) as late-stage and pre-launch spending ramped. The market capitalization of about $4.4 billion in mid-October 2026 is down from a peak near $50 per share earlier in the year, but the shares are still up about 141% year to date and about 176% over one year, so they already price in meaningful success. From here the stock is likely to move sharply on trial results, FDA interactions, and financing decisions rather than on any conventional valuation metric.

As a pre-revenue clinical-stage company, Definium has no approved products and depends on trial outcomes, FDA decisions, and continued access to capital. Late-stage data can still fail to translate into approval, and psychedelic-derived medicines face additional regulatory, scheduling, and reimbursement uncertainty given the controlled nature of the compound. The multi-billion-dollar market capitalization already reflects optimism (the shares fell about 27% over the three months to mid-October 2026 even as data kept coming in positive, a sign of how much was priced in), so disappointing results or a slower regulatory path could trigger large declines, and further equity raises would dilute existing holders. Ongoing net losses (about $354 million over the trailing twelve months) and cash burn mean the balance sheet, though currently healthy, must be watched. This is a binary, event-driven stock unsuitable for investors who need current earnings or low volatility.

18 analysts publish price targets on DFTX, averaging $72.33 against a $32.10 price as of October 2026, or +125.3%. The published targets run from $55.00 to $91.00, a moderate spread, and the ratings split 19 buy, 0 hold, 0 sell. Over the last six months there have been 7 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full DFTX forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Definium Therapeutics, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Late-stage psychiatry pipeline. DT120 ODT sits at the center of the story, with Phase 3 programs in GAD, MDD and, from 2027, PTSD. The most optimistic published target, $91.00, assumes this works close to its best case.

The case against. As a pre-revenue clinical-stage company, Definium has no approved products and depends on trial outcomes, FDA decisions, and continued access to capital. The most pessimistic target, $55.00, is roughly what DFTX is worth if this bites instead.

Read the full bull and bear case on DFTX, including what would have to change to break either one. Walnut is not an investment adviser.

Yes. Definium Therapeutics, Inc. (DFTX) has had one share split in the last 10 years:

• 1:15 on August 29, 2022, so every share held became 0.06666666666666667 shares.

A split changes the share count and the price per share and leaves the value of a holding unchanged. Someone holding $1,000 of DFTX the day before the 1:15 split held $1,000 the day after, in more shares at a proportionally lower price. Historical prices from before the date are normally shown split-adjusted, which is why a long-run chart shows no cliff.

Splits matter mainly because they make older price figures confusing to compare by hand, and because a board choosing to split is usually signalling that the price has run up far enough to feel awkward for smaller buyers. Neither is a reason to buy or sell.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Definium Therapeutics, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$0 (pre-revenue, no approved products)
• Net loss (TTM): ~$354M (Q2 2026 alone ~$159M)
• EPS (Q2 2026 actual vs estimate): ~-$1.44 vs ~-$0.55
• Cash / debt (Jun 2026): ~$1.08B / ~$36M
• Market cap: ~$4.4B
• Share price: ~$32.87 (52-week range ~$10.47-$49.70)
• Analyst mean target: ~$72 (18 analysts, strong buy consensus)

Traditional valuation multiples do not apply because Definium has no revenue and reports net losses, with consensus looking for a loss of about $3.18 per share in 2026 and about $1.94 in 2027. The roughly $4.4 billion market value, about 4x the company's ~$1.08 billion cash pile, reflects expectations for DT120's approval and launch. The company has guided that its cash funds operations into 2028, and the next quarterly report is expected around November 5, 2026.

Other names that sit close to DFTX: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get DFTX exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so DFTX sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where DFTX fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Definium Therapeutics is a well-funded but pre-revenue clinical-stage biopharma whose story is defined by Phase 3 psychiatry readouts, not by earnings. With two positive anxiety trials and one in depression now reported, the next markers are the FDA pre-NDA meeting in late 2026 and a planned NDA submission in the first half of 2027, funded by roughly $1.08 billion of cash.

Whether DFTX is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is DFTX a buy or a sell?, and where the stock could go from here in the DFTX stock forecast.

For income investors, whether DFTX pays a dividend and how the payout looks is covered in does DFTX pay a dividend? And to weigh DFTX against a peer, read the full side-by-side comparisons: DFTX vs COMP and DFTX vs HELP.